These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36313435)

  • 21. Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment.
    Wang G; Qiu C; Zhang C; Hou S; Zhang Q
    Expert Rev Hematol; 2021 Jul; 14(7):679-686. PubMed ID: 34139942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 23. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.
    Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
    Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
    Zhang Q; Zhu Z; Guan J; Zheng C
    Front Oncol; 2022; 12():904614. PubMed ID: 35814424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma.
    Zhou H; Zheng C; Huang DS
    PeerJ; 2020; 8():e9658. PubMed ID: 32844062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of endoplasmic reticulum stress-related gene signature for the prognosis and pattern in diffuse large B cell lymphoma.
    Zhang C; Lin Q; Li C; Chen Z; Deng M; Weng H; Zhu X
    Sci Rep; 2023 Aug; 13(1):13894. PubMed ID: 37626099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.
    Zhang Z; Zhao C; Yang S; Lu W; Shi J
    Lipids Health Dis; 2024 Jan; 23(1):20. PubMed ID: 38254162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.
    Hu J; Xu J; Yu M; Gao Y; Liu R; Zhou H; Zhang W
    J Transl Med; 2020 Mar; 18(1):144. PubMed ID: 32228625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and Validation of a Hypoxia-Associated Prognostic Signature Related to Osteosarcoma Metastasis and Immune Infiltration.
    Fu Y; Bao Q; Liu Z; He G; Wen J; Liu Q; Xu Y; Jin Z; Zhang W
    Front Cell Dev Biol; 2021; 9():633607. PubMed ID: 33816483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
    Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
    Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.
    Kuang Z; Li X; Liu R; Chen S; Tu J
    Front Cell Dev Biol; 2021; 9():648856. PubMed ID: 34079795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer cell-associated prognosis model characterizes immune landscape and treatment efficacy of diffuse large B cell lymphoma.
    Xiao W; Yu K; Deng X; Zeng Y
    Cytokine; 2024 Oct; 182():156726. PubMed ID: 39111113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
    Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
    Front Oncol; 2022; 12():915662. PubMed ID: 36033441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
    Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
    Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.
    Luo C; Nie H; Yu L
    Oxid Med Cell Longev; 2022; 2022():3334522. PubMed ID: 35069971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma.
    Huang S; Liu W; Zhao Q; Chen T; Huang R; Dong L; Nian Z; Yang L
    Biochem Genet; 2024 Mar; ():. PubMed ID: 38446321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer.
    Zhang F; Wang X; Bai Y; Hu H; Yang Y; Wang J; Tang Y; Ma H; Feng D; Li D; Han P
    Front Genet; 2021; 12():670384. PubMed ID: 34122523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy.
    Li Z; Duan Y; Ke Q; Wang M; Cen H; Zhu X
    Front Genet; 2022; 13():1000460. PubMed ID: 36276947
    [No Abstract]   [Full Text] [Related]  

  • 40. Roles of RNA m
    Cui W; Luo C; Zhou L; Yu T; Meng Y; Yu Q; Lei Z; Wang Y; Peng L; Luo Q; Tang D; Sun R; Yu L
    Am J Cancer Res; 2024; 14(4):1768-1783. PubMed ID: 38726285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.